<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier	#Methods/##Western blot	
name, catalogue number and RRID, if available.		

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain.	#Methods/##Cell culture	
Provide accession number in repository OR supplier name, catalog number, clone number,		
OR RRID		
Primary cultures: Provide species, strain, sex of	This experiment does not involve primary culture.	n/a
origin, genetic modification status.		

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	This experiment does not involve experimental animal.	n/a
Animal observed in or captured from the field: Provide species, sex and age where possible	This experiment does not involve experimental animal.	n/a
Model organisms: Provide Accession number in repository (where relevant) OR RRID	This experiment does not involve experimental animal.	n/a

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	This experiment does not involve plant.	n/a
Microbes: provide species and strain, unique accession number if available, and source	This experiment does not involve plant.	n/a

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	Footnote/Ethical Statement(The research ethics	
equivalent committee(s), provide reference number	committee of Harbin Medical University Cancer	
for approval.	Hospital)	
Provide statement confirming informed consent	Footnote/Ethical Statement(The research ethics	
obtained from study participants.	committee of Harbin Medical University Cancer	
Report on age and sex for all study participants.	Supplementary document2-Report on age and sex for all	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.	This study does not involve clinical trial.	n/a
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step- by-step protocols are available.	#Results	
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, or if they were not carried out.		
Sample size determination	#Methods/##Tissue samples	
Randomisation	#Methods/##Tissue samples	
Blinding	#Methods/##Tissue samples	
Inclusion/exclusion criteria	#Methods/##Tissue samples	
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	#Methods/##Statistical analysis	
Define whether data describe technical or biological replicates	#Methods	
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	This experiment does not involve human participant.	n/a
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	This experiment does not involve human participant.	n/a
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	The research ethics committee of Harbin Medical University Cancer Hospital (2013-3-1).	
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	Funding	•

<u>Analysis</u>

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is	#Methods/##Tissue samples	
excluded, and whether the criteria for exclusion were		
determined and specified in advance.		

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of	#Methods/##statistical analysis	
tests.		

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available,	#Methods/##Analysis of differential gene expression	
including protocols for access or restriction on		
access.		
If data are publicly available, provide accession	#Methods/##Analysis of differential gene expression	
number in repository or DOI or URL.		
If publicly available data are reused, provide	#Methods/##Analysis of differential gene expression	
accession number in repository or DOI or URL, where		
possible.		

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential		
for replicating the main findings of the study:		
State whether the code or software is available.	#Methods	
If code is publicly available, provide accession	#Methods	
number in repository, or DOI or URL.		

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article information: http://dx.doi.org/10.21037/gs-21-84